Olusoji Adeyi, M.D., Dr.P.H., M.B.A., is the director of Health, Nutrition, and Population Global Practice at the World Bank. He was founding director of the Affordable Medicines Facility—malaria at the Global Fund. He has led many initiatives on global, regional, and country health policies, strategies, and programs. He serves as a commissioner on the Lancet Commission on Pollution and Health, the Commission on High Quality Health Systems, and the Commission on Investing in Health. He holds a medical doctorate from the Obafemi Awolowo University in Nigeria, a master of community health from the Liverpool School of Tropical Medicine, a master of business administration from Imperial College London, and a doctor of public health from Johns Hopkins University.
Amanda BenDor, M.P.H., has more than 15 years of experience in global health and a strong focus on health systems strengthening. Currently, she provides technical and management leadership to PATH’s Digital Square and Global Health Security Partnership. For Digital Square, she manages efforts to implement the project’s global goods work; she collaborates with and supports partners who improve core software development for global goods. She also supports Digital Square’s strategic partnerships by coordinating with investors to synergize and accelerate investments that catalyze the project’s goals and objectives. Ms. BenDor is the co-chair emeritus of the Global Digital Health Network and remains on the network’s board. In that capacity, she supports events such as the annual Global Digital Health Forum. Prior to joining PATH, Ms. BenDor worked
for 12 years at IntraHealth International, where she led mHero and iHRIS implementations and supported global health workforce programs. In addition, she was the technical advisor for IntraHealth to the Knowledge for Health Project, a global family-planning, knowledge-management program funded by the U.S. Agency for International Development. Ms. BenDor received her M.P.H. from the Maternal and Child Health Department at the University of North Carolina at Chapel Hill (UNC-CH). While at UNC-CH, she also received a global health certificate and the U.S. Foreign Language Area Studies award for Kiswahili. She has a B.S. in international business and French from Meredith College.
Natasha Bilimoria, M.S.W., is the director of U.S. Strategy for Gavi, the Vaccine Alliance (Gavi), where she leads efforts to mobilize public- and private-sector support in the United States to fund childhood immunization in the world’s poorest countries. Her leadership experience and relationships with U.S. government officials, nongovernmental organizations, and the private sector have been instrumental in furthering Gavi’s visibility in the United States and throughout the global health community. Prior to assuming this role in 2013, Ms. Bilimoria served for 7 years as the president of Friends of the Global Fight, where she led U.S. efforts to support the lifesaving work of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). Previously, she held several positions at the Elisabeth Glaser Pediatric AIDS Foundation. Ms. Bilimoria also served in the Clinton administration at the White House and in the U.S. Department of the Treasury, where she worked on domestic economic development issues. She was a member of the Obama-Biden Presidential Transition Team’s state, national security, defense, intelligence, and arms-control agency-review team and led a comprehensive review and analysis of all U.S. global health programs. Ms. Bilimoria serves on the Board of Directors for Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, which is the U.S. investment arm for the Global Fund.
Cara Bradley is PATH’s chief corporate-engagement officer and leads its global strategy to expand industry partnerships to solve the world’s most challenging health problems. Her team brings together programs, countries, companies, funders, and policy makers to drive PATH’s corporate engagement activities, which focus on multi-sector partnerships that take innovation to scale and improve life for hundreds of millions of people every year. Ms. Bradley is a passionate global health advocate who has committed her career to advancing a rights-based approach to development. She joined PATH in 2015 to help expand and deepen its private-sector relationships, and she focuses on shared-value partnerships
that benefit society as well as the bottom line. Ms. Bradley has more than 12 years of experience developing groundbreaking industry partnerships and expanding the capacity of international organizations to partner with industries globally. Before joining PATH, she led a multidisciplinary European fundraising division at International Rescue Committee. Prior to that, she worked at the United Nations Children’s Fund, WaterAid, and other leading nongovernmental organizations. A native of the United Kingdom, Ms. Bradley earned her B.A. from Kent University.
Brian Brink, M.B.B.Ch., D.Med. (Hon), retired as the chief medical officer of Anglo American plc at the end of 2014. Currently, he is a non-executive director of Discovery Limited. He was awarded an honorary doctorate in medicine by the University of the Witwatersrand in recognition of his contribution to the private-sector response to HIV/AIDS in South Africa. He has been a member of the private-sector constituency on the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria since its inception in 2002. Dr. Brink has long experience in the funding and delivery of health care and remains actively engaged in discussions around universal health coverage, health systems strengthening, and public–private partnerships in health. Dr. Brink serves on several nongovernmental organization boards in the field of health and human rights, including SECTION27, Right to Care, the International Women’s Health Coalition, and GrassrootSoccer.
Donald Bundy, Ph.D., focuses on the global elimination of neglected tropical diseases (NTDs) and on the impact of disease on the health and development of children and adolescents. He currently advises the Children’s Investment Fund Foundation on developing its global portfolio on NTDs. Until 2018, he was the deputy director and a senior advisor on NTDs in the Global Health Team of the Bill & Melinda Gates Foundation, based in Seattle and London, where he reorganized and relaunched the foundation’s NTD program. Previously, as the lead health specialist at the World Bank in Washington, DC, Dr. Bundy worked for 15 years with governments in 77 low- and middle-income countries to help apply scientific rigor to the design, implementation, and evaluation of national health programs. He coordinated the World Bank response to NTDs while also partnering with the World Health Organization to lead the $1.2 billion African Riverblindness Programme (APOC). APOC harmonized the actions of more than 30 donors in 31 countries in sub-Saharan Africa to treat more than 100 million people annually. Prior to that, Dr. Bundy had a successful academic career for 20 years at Oxford University, Imperial College London, and the University of the West Indies. During that time,
he focused on the epidemiology and control of infectious disease. He has contributed to 380 publications and has produced award-winning documentary films, including a series for the U.S. Public Broadcasting Service. Currently, he is a member of the editorial team for Disease Control Priorities, 3rd Edition (DCP3).
Mona Byrkit, M.P.H., is the managing director of Global Engagement at PATH and is based in the organization’s San Francisco office. As the chief representative for PATH in the Bay Area, Ms. Byrkit is responsible for forming strategic partnerships to advance PATH’s vision: health for all. Prior to this, Ms. Byrkit was based in Hanoi, Vietnam, and led PATH’s portfolio in the Greater Mekong Subregion of Asia. Ms. Byrkit’s team introduced a wide range of innovative technologies and approaches that addressed infectious diseases; reproductive, maternal, and child health; nutrition; vaccine development; and immunization systems. Ms. Byrkit helped forge key public–private partnerships to enable health solutions, such as the introduction of fortified rice in Myanmar, access to new technologies for the prevention of HIV in Vietnam, and private-sector investments to vaccinate against life-threatening diseases throughout the Mekong region. Before joining PATH in 2009, she served as the director of CARE’s global sexual and reproductive health program. Before CARE, she was the deputy director of a global reproductive health project at IntraHealth in North Carolina. Ms. Byrkit also served as the assistant population advisor for the U.S. Agency for International Development and was based in the U.S. embassy in Turkey in the 1990s and was a Peace Corps volunteer in Senegal. In addition to her international experience, Ms. Byrkit spent several years working in U.S. domestic politics and as an advisor on health and human services in California. Ms. Byrkit has a bachelor of arts degree in international relations from Pomona College and an M.P.H. from the University of California, Berkeley. She has worked in more than 20 countries in Africa, Asia, the Middle East, and Latin America, and she speaks French, Wolof (Senegal), and basic Turkish and Vietnamese.
Rachel Cohen, M.P.P., is the regional executive director of the North American office of the Drugs for Neglected Diseases initiative (DNDi), an international not-for-profit research and development organization that discovers and develops new medicines for several neglected tropical diseases, pediatric HIV, hepatitis C, and, through a joint initiative with the World Health Organization called the Global Antibiotic Research and Development Partnership, serious drug-resistant infections. Prior to joining DNDi in 2011, Ms. Cohen worked for Doctors Without Borders/-
Médecins Sans Frontières (MSF) from 1999 to 2010. She served as the head of mission for MSF in South Africa and in Lesotho for 4 years and oversaw numerous medical programs that were primarily focused on HIV/AIDS and drug-resistant tuberculosis. Before working for MSF in the field, Ms. Cohen was the U.S. director of MSF’s Access to Essential Medicines Campaign. From 2009 to 2015, she served on the Board of Directors of MSF’s Operational Center in Brussels. Prior to working with MSF, Ms. Cohen was the director of Foundation and Corporate Giving at Housing Works, the largest minority-controlled AIDS service organization in the United States. Before that, she served as the program coordinator for the U.S.+Cuba Medical Project, where she directed medical aid, education, and advocacy programs. Ms. Cohen earned her master in public policy with a certificate in health and health policy from Princeton University’s Woodrow Wilson School of Public and International Affairs.
Brenda D. Colatrella, M.B.A., is the associate vice president of Corporate Responsibility at Merck & Co., Inc. (Merck), where she is responsible for the development, implementation, and reporting of Merck’s global corporate responsibility approach on environmental, social, ethical, and governance issues in alignment with the company’s business strategy. She also oversees several of Merck’s global health partnerships and relationships with key partners and is involved in developing policies that help expand access to medicines, vaccines, and quality health care—particularly in the developing world and in emerging markets. She also serves as president of the Merck Foundation, a private charitable foundation that was established in 1957. It is based in the United States, funded entirely by Merck, and represents Merck’s chief source of funding support for qualified nonprofit charitable organizations. Ms. Colatrella is also the president of the Merck Patient Assistance Program, which provides free Merck medications and adult vaccines to eligible individuals in the United States who need such resources but lack access to them through insurance coverage and cannot afford to pay for them otherwise. Prior to leading the corporate responsibility division, Ms. Colatrella was the executive director of Global Health Partnerships within the division. There, she was responsible for key global health and access partnerships and for Merck’s relationships with a wide range of stakeholders in the global health arena. She was also the executive director of HIV Policy and External Affairs for the Europe, Middle East, Africa, and Canada region and primarily focused on driving Merck and industry initiatives to improve access to HIV/AIDS care and treatment in the developing world. In addition, she was the senior vice president of the Merck Foundation and the senior director in its Office of Contributions. In these roles, she was responsible for all foundation and
corporate cash grant-making activities and product donations programs (e.g., the Merck Mectizan Donation Program). Ms. Colatrella received her B.A., summa cum laude, from Muhlenberg College and was a member of Phi Beta Kappa. She completed her M.B.A. at New York University’s Stern School of Business where she received the Dean’s Award. She has published several articles on the Mectizan Donation Program, on the role of the private sector in global health, and on successful public–private partnerships.
James Coughlan leverages 30 years of experience with The UPS Foundation as the former global president of United Parcel Service (UPS) Customer Solutions to provide design expertise on supply chains to The UPS Foundation and its humanitarian partners. After he retired from UPS, Mr. Coughlan became a supply chain expert on mission for The UPS Foundation to fulfill his passion to engage the humanitarian sector. He currently provides support for the supply-chain-strengthening and capacity-building efforts of leading humanitarian agencies.
Shawn Dolley is the director of management consulting for Life Science and Health Care at Cloudera and a “transformation coach” for customers as they move toward an artificial intelligence (AI) and big-data-driven approach to informatics. Mr. Dolley provides advice on use cases in research, discovery, and outcomes and on translational medicine and population health. His work includes convening and supporting public–private partnerships in global health. Prior to this role, Mr. Dolley was an industry leader for health and life science, and he set Cloudera’s vision, roadmap, solutions, and partnerships in areas such as precision medicine, real-world evidence, and clinical prediction. Prior to his work at Cloudera, Mr. Dolley led the health care and life science industry practice at Netezza. When IBM acquired Netezza, Mr. Dolley joined the public-sector industry practice for IBM. Mr. Dolley also designed a Health Outcomes Analytic Appliance in conjunction with Brigham and Women’s Hospital and Harvard Medical School. Mr. Dolley has worked in analytics since 1995. He is a member of the Global Alliance for Genomics and Health and of the Observational Health Data Sciences and Informatics Collaborative. Mr. Dolley is on the Board of Advisors for Precision Medicine at Brigham and Women’s Hospital and is a board member of Predict Align Prevent, a new program that uses predictive analytics to prevent child abuse and neglect. He was recently named one of Washington, DC’s “Fifty on Fire,” a list of the 50 most innovative people or companies in the district. Today, he primarily focuses on precision public health, global computational epidemiology, and open source technology.
Clarion Johnson, M.D., co-chair of the Forum on Public–Private Partnerships for Global Health and Safety, served as the global medical director of ExxonMobil Corporation until his retirement in 2013. Currently, Dr. Johnson is a consultant to ExxonMobil, the immediate past chair of the Joint Commission’s International and Resource Boards, and a member of the Yale School of Public Health Leadership Council. He serves on several boards, including those at the Bon Secours Hospital System, the Yale School of Public Health, and the Milbank Memorial Fund. Dr. Johnson previously served on the Board on Global Health at the National Academies of Sciences, Engineering, and Medicine. Dr. Johnson also holds a secretary appointment from the U.S. Department of Health and Human Services to the Advisory Board of the National Institute for Occupational Safety and Health and was a member of the Governor’s Task Force on Health Reform in Virginia and a co-chair of the Governor’s Task Force on Insurance Reform. He is the past chair of the Virginia Health Care Foundation and of the board of City Lights Charter School in Washington, DC. He served as an advisor and a lecturer in the Harvard Medical School’s Department of Continuing Education “Global Clinic Course” from 2005 to 2008. In 2013, he received the President’s Award from the Oil and International Petroleum Industry Environment Conservation Association and from the Oil and Gas Producers for contributions to health, and in 2012, he received the Society of Petroleum Engineers Award for Health, Safety, Security, Environment, and Social Responsibility. In 2011, he received a medal from the French Armed Forces Institute De Recherche Biomedical for Project Tetrapole, a public–private partnership in malaria research. Dr. Johnson is a graduate of Sarah Lawrence College, as well as a member of its board of trustees, and of the Yale School of Medicine. While on active duty in the U.S. Army, he also trained as a microwave researcher at the Walter Reed Army Institute of Research. He is board certified in internal medicine, cardiology, and occupational medicine.
Wiweka Kaszubska, Ph.D., is the head of product development at Medicines for Malaria Venture (MMV), which is based in Geneva, Switzerland. MMV’s mission is to bring new, effective, and affordable medicines to malaria-endemic countries and, ultimately, to eradicate disease. Dr. Kaszubska is responsible for the late-stage development portfolio of antimalarial drugs. Her team works in close partnership with pharmaceutical organizations to develop and register new medicines for malaria-endemic countries. Prior to joining MMV in 2012, she was the head of the Global Product Unit for Autoimmune and Inflammatory Therapeutic Area at Merck Serono in Geneva. Dr. Kaszubska started her career in discovery research at Abbott Laboratories in Chicago in the metabolic disease area.
In total, she has more than 15 years of experience in the global pharmaceutical industry across all phases of drug development. Dr. Kaszubska holds a Ph.D. in biochemistry from the University of Illinois and a B.S. in chemistry from The University of Chicago.
Seema Kumar, M.Sc., is the vice president of Innovation, Global Health, and Science Policy Communication at Johnson & Johnson (J&J). In this role, Ms. Kumar works to position J&J as a global pioneer in innovation and in research and development (R&D) and as a partner of choice. Her responsibilities include communications about enterprise innovation and R&D, medical safety and ethics, policy, and global health. She also serves as the communication leader for the Johnson & Johnson R&D Management Committee and for the Johnson & Johnson Innovation Centers. Ms. Kumar previously served at the Janssen Pharmaceutical Companies of J&J as the vice president of Enterprise Innovation and Global Health Communication and as the vice president of Global R&D Communications. Prior to joining J&J, Ms. Kumar was the chief communications officer at the Whitehead Institute for Biomedical Research/Massachusetts Institute of Technology Center for Genome Research, the flagship center for the Human Genome Project. Ms. Kumar holds a master of arts in science journalism from the University of Maryland and completed a fellowship at the National Cancer Institute. She received a bachelor of science and communication from the University of Maryland and a bachelor of science in physics from Stella Maris College in Madras, India.
Oren J. Schlein, J.D., brings 20 years of experience as an attorney and a philanthropic adviser to the United Nations Children’s Fund (UNICEF), where, as the senior adviser for Global Philanthropy, he leads the organization’s global foundations portfolio, including the strategic refresh of the UNICEF/Gates Foundation partnership. He is committed to maximizing the social impact of philanthropic investments through innovative partnerships grounded in high-impact interventions that are measurable, cost-effective, sustainable, and scalable. After an early career as a banking and corporate attorney, Mr. Schlein moved into the development field and first worked for the United Nations Association, the largest advocacy organization that supports United Nations causes in the United States. In the mid-2000s, as the senior adviser for the United Nations Development Programme in the Maldives, Mr. Schlein led efforts to mobilize private and public resources in response to the 2004 Asian tsunami. In the late 1990s, he served as the executive director of the international Adopt-A-Minefield® Campaign, which gained widespread public attention through the support of its Goodwill Ambassador, Sir Paul McCartney. Mr. Schlein
holds a juris doctor from the Boston University School of Law and a bachelor of arts in international relations from Johns Hopkins University. He is fluent in French and conversant in Mandarin Chinese.
Gaudenz Silberschmidt, M.D., D.T.M.P.H., M.A., joined the World Health Organization (WHO) in 2012 as an advisor to the director-general on reform issues. He was appointed the director for Partnerships and Non-State Actors in February 2015, responsible for the process leading to the adoption of the Framework of Engagement with Non-State Actors, and he acted as the director of Coordinated Resource Mobilization from 2014–2017. Before joining WHO, he was the Swiss Ambassador for Global Health, heading the International Affairs Division of the Swiss Federal Office of Public Health from 2003–2012. Dr. Silberschmidt received his medical degree from the University of Zurich, holds a master’s degree in international relations from the University of St. Gallen and a diploma in tropical medicine and public health from the Swiss Tropical and Public Health Institute in Basel.
Peter Singer, OC, M.D., M.P.H., FRSC, is the special advisor to Dr. Tedros Adhanom Ghebreyesus, the current director-general of the World Health Organization. He is also a professor of medicine at the University of Toronto and was the chief executive officer of Grand Challenges Canada. In 2011, Dr. Singer was appointed an Officer of the Order of Canada for his contributions to health research and bioethics and for his dedication to improving health in developing countries. In 2007, he received the Michael Smith Prize as Canada’s Health Researcher of the Year in Population Health and Health Services. He is a fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, the U.S. National Academy of Medicine, and the Academy of Sciences for the Developing World.
Rebecca Stevens is the head of Access Partnerships and Public Affairs at Novartis Social Business.
Wendy Taylor, M.P.P., is a fellow at The Rockefeller Foundation.
Mary Lou Valdez, M.S.M., is the associate commissioner for international programs at the U.S. Food and Drug Administration (FDA) where she leads the Office of International Programs staff in China, Europe, India, and Latin America and at FDA headquarters. She is responsible for catalyzing FDA global engagement in collaboration with FDA centers and offices, international health and regulatory partners, ministries of health
and agriculture, other U.S. government agencies, industry, academia, multilateral organizations, and related stakeholders.
Bruce Wilkinson, M.B.A., is the chief executive officer of the Catholic Medical Mission Board (CMMB). To the field of global poverty alleviation, he brings deep experiential understanding of and commitment to individual empowerment in support of sustainable solutions. His strategic and operational experiences span 30 years in Africa, 7 years in Washington, DC, and 3 years in Europe across sectors of applied linguistics, education, maternal and child health, humanitarian assistance, economic development, agriculture, and HIV/AIDS. Inspired as a Peace Corps volunteer in Ghana and by his time at the Summer Institute of Linguistics in Mali, he has acquired expertise in virtually all areas within CMMB’s focus, including volunteerism, work with gifts-in-kind and corporate engagement, and programming for maternal and child health. During his 25 years at World Vision, he was instrumental in mobilizing the U.S. commitment toward The U.S. President’s Emergency Plan for AIDS Relief; served as the chief of party for the 5-year, $250 million, U.S. Agency for International Development–funded RAPIDS initiative, which cared for 260,000 Zambian orphans and vulnerable children; led nine country programs with an annual budget of $450–$600 million; and established a strong track record in policy influence for developing countries. He has a B.A. in economics from Gordon College and an M.B.A. in international management from Cambridge University, England, with additional diploma studies in linguistics, French, and anthropology.